Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test
Avacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test
Read moreAvacta Focusing On Full Clinical Validation Of Rapid Covid-19 Test
Read more(Sharecast News) - Avacta Group responded to some press speculation on take-up of its lateral flow SARS-CoV-2 rapid antigen test for Covid-19 by the UK government on Monday.
Read moreLONDON MARKET OPEN: European Equities Slip Amid Inflation Fears
Read moreIN BRIEF: Avacta Gets Phase I Clinical Trial Approval For AVA6000
Read more(Sharecast News) - Biotherapeutics and reagents developer Avacta has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) for a phase 1 study of its lead 'preCISION' pro-drug, AVA6000 pro-doxorubicin, it announced on Thursday.
Read moreAIM WINNERS & LOSERS: Cornish Metals Jumps 40% On AIM Debut
Read moreAvacta Shares Surge On Positive Data For Covid-19 Antigen Test
Read more(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK, it announced on Tuesday.
Read more(Sharecast News) - Biotherapeutics developer Avacta Group has entered into a commercial partnership with Mologic, it announced on Monday, to accelerate to market its 'AffiDX' SARS-CoV-2 lateral flow rapid antigen test.
Read moreAIM WINNERS & LOSERS: Bahamas Petroleum Sinks As Pulls Plug On Well
Read moreAvacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test
Read moreTRADING UPDATES: Asiamet Hits Back At Shareholder; Hardide Raises Cash
Read more(Sharecast News) - Biotherapeutics developer Avacta Group announced on Monday that its joint venture with Daewoong Pharmaceutical, AffyXell Therapeutics, has closed a series A venture capital investment of $7.3m (£5.32m) to further develop its pipeline of next generation cell and gene therapies.
Read moreIN BRIEF: Avacta Lands Deal With Bruker To Assess SARS-CoV-2 Test
Read moreIN BRIEF: Avacta Group Enters License Agreement With Point Biopharma
Read more